Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Betacoronavirus/isolation & purification , Coronavirus Infections/complications , Critical Care/organization & administration , Dermatitis, Exfoliative/drug therapy , Pneumonia, Viral/complications , Psoriasis/drug therapy , Thalidomide/analogs & derivatives , COVID-19 , Coronavirus Infections/virology , Dermatitis, Exfoliative/complications , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/virology , Psoriasis/complications , SARS-CoV-2 , Thalidomide/therapeutic useSubject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Dermatology/organization & administration , Infection Control/organization & administration , Pneumonia, Viral/epidemiology , Psoriasis/therapy , COVID-19 , Coronavirus Infections/prevention & control , Humans , Italy , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , SARS-CoV-2ABSTRACT
BACKGROUND: The number of elderly patients with psoriasis is steadily increasing in the Western world; nevertheless, they are frequently excluded from biological clinical trials and described as a high-risk group for adverse events. Thus, there is lack of information concerning safety and effectiveness of available treatments for psoriasis in the elderly, particularly about new biological systemic drugs. OBJECTIVE: Our aim was to describe our experience with all biological therapies currently used in the elderly (>65 years) psoriatic patients. METHODS: A retrospective multicentric review of clinical records of all psoriatic patient aged 65 years or older actually receiving biological drugs (etanercept, adalimumab, infliximab, golimumab, certolizumab pegol, ustekinumab or secukinumab) was undertaken. RESULTS: Our study population included 266 elderly psoriatic patients actually receiving any biological therapy (adalimumab 31.2%, ustekinumab 28.9%, etanercept 20.3%, secukinumab 15%, infliximab 3%, golimumab 1% and certolizumab pegol 0.6%). The PASI score at the baseline (week 0) ranged from 4 to 54; mean ± SD, 16.5 ± 7.1, which changed after biological administration to 3.7 ± 8 at week 16, 1.6 ± 2.1 at week 28 and 1.2 ± 2.1 at week 52. Among 266 elderly psoriatic patients, 25 adverse events were reported during the observation period. The most frequent events were infections with 12 (48%) reports, followed by malignancies with four (16%) reports. CONCLUSIONS: To date, our study represents the widest experience on the use of biological drugs in elderly psoriatic patients. We found that all biologics for psoriasis showed a great efficacy also in elderly people, and the rate and the type of adverse effects were similar to the younger patients. In conclusion, the age alone should not limit our therapeutic options. Further observational study using multiple data sources is needed to evaluate long-term effectiveness and safety for elderly psoriatic patients.
Subject(s)
Biological Products/therapeutic use , Dermatologic Agents/therapeutic use , Psoriasis/drug therapy , Adalimumab/therapeutic use , Aged , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Biological Products/adverse effects , Certolizumab Pegol/therapeutic use , Dermatologic Agents/adverse effects , Etanercept/therapeutic use , Female , Humans , Infliximab/therapeutic use , Italy , Male , Retrospective Studies , Severity of Illness Index , Treatment Outcome , Ustekinumab/therapeutic useSubject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Dermatologic Agents/administration & dosage , Psoriasis/drug therapy , Adult , Antibodies, Monoclonal, Humanized/adverse effects , Dermatologic Agents/adverse effects , Drug Administration Schedule , Drug Substitution , Female , Humans , Injections, Subcutaneous , Interleukin-17/antagonists & inhibitors , Interleukin-17/immunology , Male , Middle Aged , Psoriasis/immunology , Treatment OutcomeSubject(s)
Antibodies, Monoclonal/therapeutic use , Psoriasis/drug therapy , Adult , Aged , Antibodies, Monoclonal, Humanized , Dermatitis, Exfoliative/drug therapy , Dermatitis, Exfoliative/etiology , Humans , Male , Middle Aged , Psoriasis/complications , Psoriasis/pathology , Remission Induction , Skin Diseases, VesiculobullousABSTRACT
AIM: The aim of this study was to provide practical recommendations for optimizing the use of conventional and biological systemic treatments for moderate-severe chronic plaque psoriasis, particularly in case of transitioning and switching. METHODS: A total number of 147 dermatologists from 33 different countries including Italy achieved consensus in providing practical recommendations for the use of conventional and biological treatments for moderate to severe psoriasis based on systematic literature review and/or expert opinion. RESULTS: In general, the continuous treatment regimen should be preferred in order to achieve a complete and long-term control of psoriasis. However, the treatment could be stopped or the dose reduced in case of complete disease clearance. A conventional drug could be associated to biological treatment in selected cases. Transitioning and/or switching could be considered in case of inefficacy or intolerance. A period of wash up is required if transitioning or switching is due to safety issues. CONCLUSION: This study provides practical suggestions for the optimal use of conventional and biological treatments for chronic plaque psoriasis.
